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. Many view biometric monitoring devices (BMDs) as the path to a deeper understanding of disease pro cesses and the status of patients 2 . The litera ture describes these devices using various terms, including digital biomarkers, digital measurement devices, technologyobserved measures and biometric monitoring systems. We define a BMD as a biosensor that collects objective data on a biological recognition ele ment (for example, blood glucose or sodium levels), anatomical structure (for example, tumour size, infarct size or hippocampal vol ume) or integrated physiological para meter (for example, heart rate, blood pressure, electro encephalography, mobility, speech and sleep patterns, social engagement or speed of information processing). These BMDs utilize algorithms to transform these data (signal output) into a format that is interpretable as a specific measure or an aggregate functional outcome [3] [4] [5] [6] [7] [8] . Health platforms using biom etric monitoring allow efficient collection of realtime highfrequency data with decreased inclinic assessment time, and dramatically reduce sample size to see population effects 9 . BMDs can measure minimally observ able changes in characteristics of patients to a higher level of resolution than possible with clinical observation. It is crucial to identify these earliest reliable measures of disease if we are to meet the goal of preventing or mini mizing the impact of conditions on the lives of patients. For example, clinical trials in neu rodegenerative diseases are becoming increas ingly focused on earlier stages of disease to identify individuals who are genetically or otherwise susceptible prior to them develop ing symptoms. These studies aim to identify the earliest signs in the presymptomatic stage, well before the disease has caused major neu rodegenerative damage. Disease is character ized both by symptoms -phenomena that patients report (patientreported outcome measures (PROs)) -and signs, which are observable measures that are often recorded by evaluatorrelated means and observer reported outcomes, or directly measured via performance outcomes (FIG. 1) . The ability of these devices to continuously, remotely and relatively unobtrusively record physical signs increases statistical power, enhancing both the sensitivity and specific ity of change detection in those monitored 9 . By observing personal health and behaviour signs frequently (potentially continuously), reliable assessment of change is more likely. As digital drug development tools (dDDTs), BMDs may objectively augment PROs, and be integrated into the diagnosis, prognosis and treatment of patients. BMDs may iden tify evolving patterns of perceived normal function, reflecting a harbinger of an ensuing chronic disease state. Furthermore, the abil ity to measure early signs may enable more precise identification of phenotypic variants of a disease and allow better stratification of relevant subpopulations. In some cases, real time data acquisition with BMDs may even enable statistical comparisons within an indi vidual 9 , supporting the practice of personal ized medicine. In the longterm, the clinically relevant and actionable data created by BMDs may provide a more comprehensive view of the interrelated biochemical, structural, phys iological and behavioural dynamics that occur during health, disease and treatment.
Unfortunately, a lack of clarity remains regarding the appropriate use of BMDs as tools to support drug registration trials. This gap was recently underscored by the newly appointed commissioner of the US FDA, Scott Gottlieb, who announced that the FDA will pilot a new approach towards regulation of digital health tools later this year (see Further information). This commentary provides a highlevel roadmap, agnostic to therapeutic area, of key considerations to advance BMDs as objective assessments of clinically relevant end points for capturing the patient's experi ence in clinical trials, and in realworld obser vational studies. These considerations were developed by the member organizations of the Coalition Against Major Diseases (CAMD; see Further information). This consortium, founded in 2008, is one of 14 public-private partnerships of the Critical Path Institute, and focuses on creating new drug development tools and methods that advance regulatory science to accelerate the delivery of innova tive treatments for various stages of Alzheimer disease, and neurodegenerative diseases with related cognitive and functional impairments.
Key considerations for BMDs
Defining the concept of interest and the context of use. Clear interpretation of data requires careful prespecified definitions of the information assessed. Therefore, a pri ority to advance this rapidly evolving field is to methodically define the concept of interest (COI) that a given BMD would measure. In turn, the factors involved in developing and validating a COI will help frame an appro priate context of use (COU) that will be required for drug development clinical trials. Considerations for the conceptual founda tions for qualification of clinical outcome assessments by the FDA, and the develop ment of COIs and COUs, have been recently communicated 10 . Thus, before a BMD can be evaluated for use in a registration study as a dDDT, a rigorous path of validation must be followed (TABLE 1) .
Data standards. One of the opportunities in efficient scaling of BMDs for clinical research is development of data standards. Currently, there is no interoperable uniformity for BMDderived data. Development of uniform data standards (for example, through adop tion of Clinical Data Interchange Standards Consortium (CDISC) methods) would pro vide a scientifically based consensus on the way to record, structure and report data generated by BMDs. CDISC Foundational Standards provide "the basis for the com plete CDISC suite of standards, supporting the clinical and nonclinical research process from protocol through data collection, data exchange, data management, data analysis and reporting" ( Although not yet formally validated as a clinical outcome assessment (COA), medication adherence has been shown to be decreased by as much as 40% in those with mild cognitive impairment. c | For many chronic diseases, the clinical instruments used to quantify disease are validated only during manifest disease, and there is a strong need to begin treatment earlier in the disease course, as indicated in the figure, which could be enabled by BMDs . Claims regarding the benefits of BMDs should include the analytical and clinimetric validity of the devices and the clinical utility of the measured end points (see 'What the Fitbit lawsuit means for clinical researchers' in Further information). With the increased emphasis on prevention therapies, the need to identify sensitive outcome assessments is growing. Otherwise, long ( 5+ year) trials will be necessary before the effects of early interventions can be determined. Both the health care community and regulators are embracing this need, and analysis of BMD data is anticipated to provide patient-centred, real-world evidence to support regulatory and clinical decision-making (see 'Use of real-world evidence to support regulatory decision-making for medical devices: draft guidance for industry and Food and Drug Administration staff' in Further information). PRO, patient-reported outcome.
areas that are common across all studies such as demographics, medical history, medication history and concomitant medications, adverse events and other common domains. The standardization of how data are col lected, stored, labelled and tagged allows for the exchange of information, facilitates the pooling of data from different devices, and allows contextualization of the data. For example, recording the timing of data col lection of blood glucose readings is critical metadata for understanding whether the measurement occurs after fasting or imme diately after a meal. Similarly, when shar ing data from multiple actigraphy devices, labelling and tagging data with instrument properties and preprocessing will support data pooling. Providing contextualization and standardization will reduce dependence on blackbox and proprietary algorithms, making data comparable at all stages of processing. This would enable processing steps themselves to be treated as a form of data and tracked in the same standardized ontologies in which the data and metadata themselves belong.
Good clinical practice.
Within the phar maceutical industry, the use of BMDs for exploratory work or internal decision making is becoming a more routine prac tice. Development of Good Clinical Practice (GCP) standards will be crucial to enable the ethical and correct use of BMDderived data from laterstage clinical trials for regulatory submission (TABLE 1) .
Creating a global ecosystem. Creation of a unified, global, precompetitive BMD eco system including both the medical device and drug development spaces would advance the necessary conversations and provide a network of experts to implement BMD use in future routine health care manage ment (TABLE 1) . These experts would include clinicians, data scientists and managers, psychometricians, pharmacometricians, pharmacoeconomists, regulators and statis ticians from the device and pharmaceutical industries, regulatory agencies, academia and government. Accomplishing this objec tive would augment the ongoing US Precision Medicine Initiative, and could provide an evidencebased path to integrate both clini cal drug trial and realworld data.
A unified lexicon of precise terminologies for the potential multitude of BMDs is needed to facilitate dialogue in this community. The glossary developed by the FDA-NIH working group (BEST -Biomarkers, EndpointS, and other Tools -Resource; see Further informa tion) can serve as an important foundation to develop this lexicon. Standardized data sharing would increase the efficiency of BMD development and accelerate the iterative learning required to support outcome assessments for a particular COU. Multiple organizations are pursuing the advancement of BMDs in parallel, but a lack of appropriate incentives, coupled with insuf ficient allocation of resources, have created substantial barriers to sharing and assembling patientlevel data. One step to help address this could be the establishment of a data sharing consortium to generate consensus on data standards to accelerate the use of BMDs in clinical drug development.
Providing consensus guidelines for what constitutes sufficient or necessary validation of BMDs depends on the COU and the related healthcare decisions. However, if BMDs are used in future registration studies, BMDs should undergo the same psychometric vali dation process as other clinical outcomes assessments (such as PROs) to be considered reliable and valid measures. Realtime data acquisition with BMDs can enable statistical comparisons within an individual, support ing the practice of personalized medicine. Integration of existing standards with novel methods will require rigorous crossvalida tion and testing by the medical community. Active dialogue with the regulators is imper ative before this work is initiated, and must happen periodically, at important decision points.
Overall, by involving multiple stake holders in precompetitive, public-private partnerships, the community could align on principles and advance a clear roadmap to develop, validate and standardize the use of BMDs in various diseases.
